The Pet Care Market size is estimated at $ 20.02 billion in 2024, and is expected to reach $ 24.59 billion by 2029 according to a report published by Mordor Intelligence. In relation to this, the Indian market wasn’t growing that rapidly until COVID-19. Reports show that the pet care market in India has experienced a CAGR of 16.5 percent post pandemic. However, the retail segment for pet care products along with majority of veterinarians in India face various challenges regarding high input costs, unavailability of medicines and scarcity of quality native manufacturing entities.
First is the dependency on imported products that incur high capital inputs. Second is the unavailability of medications at all locations that lead to the usage of human medicines on pets. Last but not the least, manufacturing of specialized medications is still unavailable in India and only traditional formulations can be found in the market.
AREIONVET has emerged as the native manufacturer and supplier for a complete range of pet care products that were not available in India before. Product innovation is the primary motto of the company as it aims to become a substitute for all the formulations that get imported to India. Manufacturing problems also exist in this industry for companies as they have to be dependent
upon third party manufacturers which affect the final quality of products.
Operational Excellence
Owing to immense technical expertise and experience of the market, AREIONVET has been successful in creating unique formulations that were not available in the market before. The manufacturing unit of the company is GMP certified and ISO 22000 certified and follows all regulatory guidelines for manufacturing pet care products. The company’s R&D is headed by Vivek Gejji, who has 39 years of experience and highly qualified individual in this domain.
The Indian pet care products market was able to experience several products for the first time through AREIONVET and all the credit goes to the R&D department of the company. “We developed a medication for hairball formation in cats that was not available in the Indian market and was being imported at high costs. We were able to develop a standard formulation for that product and were successful in lowering the price as well,” says Saumya Tripathi, Managing Partner & CEO, AREIONVET.
We opened our own manufacturing unit in 2017 & more than 90 percent of our products are manufactured in-house. We are in the process of manufacturing specialized formulations that are not available elsewhere in the country
Looking at the Future
Since its inception in 2011, AREIONVET has gained considerable trust and recognition in the market with in-house manufacturing of quality products and its vision of adding value to the market. Looking ahead, the company has observed several more gaps which it aims to fill. The company is in the process of collaborating with an Indian rapid kit manufacturer to develop rapid tests kits for dogs and cats. With the help of these, the virus can be detected in a few minutes and medications can be given to a patient.
“We have also observed gaps in the wildlife medication domain of the country. Most of the health practitioners lack basic medications like dewormers for wildlife animals and are forced to use alternative medicines which are not easily available and are costly, which is why we are in the process of coming up with our own product range for wild animals in the coming few years. From April, 2024, we will also be available Pan India. We want to expand our presence in the other Asian countries and the Gulf region as well”, concludes Saumya.
.jpg "Artificial Intelligence to Revolutionize Advanced Chip Design")
